Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
Status:
Completed
Trial end date:
2020-03-06
Target enrollment:
Participant gender:
Summary
This study will be conducted in subjects with established Parkinson's disease in 2 parts.
Part A will examine the tolerability, safety, and pharmacokinetics of AZ-009 dose escalation
; and Part B will assess the tolerability, safety, pharmacokinetics, and pharmacodynamics of
AZ-009 compared with placebo in a crossover design